|
|
Volumn 468, Issue 7320, 2010, Pages 18-19
|
|
'Biosimilar' drugs poised to penetrate market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
BEVACIZUMAB;
BIOSIMILAR DRUG;
DRUG;
ERYTHROPOIETIN;
GENERIC DRUG;
GRANULOCYTE COLONY STIMULATING FACTOR;
HUMAN GROWTH HORMONE;
INFLIXIMAB;
RITUXIMAB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
BREAST CANCER;
COLORECTAL CANCER;
DRUG LEGISLATION;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
NONHODGKIN LYMPHOMA;
NOTE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
BIOLOGICAL AGENTS;
BIOTECHNOLOGY;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, GENERIC;
EUROPE;
HUMANS;
MARKETING;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 78149269335
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/468018a Document Type: Note |
|
Times cited : (35)
|
|
References (0)
|
